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Abstract
Globally, health research organizations are called upon to re-examine their policies and practices
to more efficiently and effectively address current scientific and social needs, as well as increasing
public demands for accountability.
Through a case study approach, the authors examine an effort undertaken by the National Institute
of Allergy & Infectious Diseases (part of the National Institutes of Health, Department of Health &
Human Services, United States Government) to develop an evaluation system for its recently
restructured HIV/AIDS clinical trials program. The challenges in designing, operationalizing, and
managing global clinical trials programs are considered in the context of large scale scientific
research initiatives.
Through a process of extensive stakeholder input, a framework of success factors was developed
that enables both a prospective view of the elements that must be addressed in an evaluation of
this research and a current state assessment of the extent to which the goals of the restructuring
are understood by stakeholders across the DAIDS clinical research networks.
Introduction
Around the globe, health research organizations are
examining ways of designing, managing and evaluating
their programs so they address local and international
health needs and achieve maximum value for their
investments. These practical concerns are sparking inter-
est in research on health systems research, in order to
improve results and create an evidence base that can
guide policy-makers on the management of health
research [1].
This manuscript describes the process and progress to date
in developing a systematic approach to support the evalua-
tion of a global human immunodeficiency virus (HIV) clin-
ical trials research program. Further, it analyzes and draws
inferences from this specific work that may have broad
applicability for the management, operationalization, and
evaluation of other large-scale research endeavors.
The specific case study highlighted here is situated in the
recent restructure of the world's largest human immuno-
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(HIV/AIDS) clinical trials program. We begin by reviewing
the program's context, its scientific goals and objectives,
rationale for the restructure, and how the factors that
drove the restructure were addressed in the restructuring
plan. We then focus on the development of a conceptual
framework as the foundation of a larger evaluation sys-
tem, emphasizing the process and results of a stakeholder-
driven effort to describe the success factors for the newly
restructured program. We discuss the resulting framework
in the context of the program's goals and its implications
for the evaluation of other large scale research endeavors.
Background on the transformation of science
In recent years, there has been a broad transformation of
the organization and management of science in the
United States [2,3]. In addition to traditional support for
individual scientists working on their own, federally
funded scientific research now emphasizes "big science":
large, collaborative research initiatives, with annual budg-
ets of $5 million or more. The number of these types of
initiatives has increased in recent years [4].
One major type of "big science" is clinical research net-
works of which the HIV/AIDS clinical networks described
in this manuscript are a prominent example. There are
nearly 300 clinical research networks in the United States
and Canada. The majority are funded primarily by the US
Government and nearly half carry out clinical trials as their
primary activity [5]. Non-trial studies include observational
research, outcomes research or best practice modeling.
Another type of "big science" is the extramural research
center structure, first funded in the 1960s. There are now
more than 1200 center programs, with each of the
National Institutes of Health (NIH) institutes using this
approach [6]. These programs generally take a multi-disci-
plinary team approach focused on interaction between
basic and clinical researchers to foster translational
research.
Large research initiatives generally have broader goals
than traditional individual investigator-initiated grants
[7]. In addition to providing scientific outputs, these
multi-million dollar, multi-institutional programs are
also expected to foster multi-disciplinary teamwork, pro-
vide more effective support for independently funded
investigators, gain increased attention to a program's
research by the center's home institution, recruit estab-
lished researchers to the program's area of interest,
develop new investigators, expand the education of health
professionals and the general public, build scientific infra-
structure and demonstrate state-of-the-art prevention,
diagnosis and treatment techniques. Ultimately, the effi-
ciencies and synergism inherent in these systems of
research are expected to positively impact population
health and behavior by producing innovative, relevant,
and timely research. These broader goals, and the opera-
tional activities that support them, must be taken into
account when developing evaluation approaches [3].
Thus, the multiplicity of goals and stakeholder agendas
which these research enterprises simultaneously pursue,
poses substantial management, implementation and eval-
uation challenges. At the same time, there are growing
pressures for accountability for federally funded scientific
research [8-11], and recent law to include performance
monitoring officers. [12,13].
Leading scientific bodies, responding to government
expectations, have issued their own recommendations for
the evaluation of scientific research endeavors [6,14-16].
This paper explores the management and evaluation chal-
lenges associated with the HIV/AIDS clinical research net-
works. Through a case-study approach, we describe a
participatory process applied in this setting to construct a
conceptual framework, and explore the utility of the
framework to shape a system of network evaluation.
Background on the NIAID Division of AIDS and 
its clinical trials networks
The Division of Acquired Immunodeficiency Syndrome
(DAIDS) is one of three extramural scientific divisions of
the National Institute for Allergy and Infectious Diseases
(NIAID), the second largest of the 27 institutes and cent-
ers that comprise the U.S. National Institutes of Health
(NIH). Established in 1986, the mission of DAIDS is to
help ensure an end to the HIV/AIDS epidemic by increas-
ing basic knowledge of the pathogenesis and transmission
of the human immunodeficiency virus (HIV), supporting
the development of therapies for HIV infection and its
complications and co-infections, and supporting the
development of vaccines and other prevention strategies.
With an annual budget of approximately one billion dol-
lars, DAIDS is a major source of funding for biomedical
research around the world.
Beginning with the AIDS Treatment Evaluation Units in
1987, DAIDS goal in establishing the HIV/AIDS networks
was to assemble multidisciplinary scientific expertise, and
create sustainable, reusable capacity and infrastructure to
support a long-term commitment to clinical trials. The
ensuing 19 years witnessed significant scientific advances
as well as major changes in the global demographics of
HIV/AIDS, presenting both challenges and opportunities
for research. In response, the DAIDS networks have
evolved and adapted. An overview of the history and evo-
lution of the DAIDS networks is shown in Figure 1.Page 2 of 16
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In 2001, several factors, including the size and complexity
of the network enterprise, changes in the HIV/AIDS
knowledge base, unabated expansion of the epidemic in
the developing world, and fiscal considerations,
prompted the DAIDS leadership to reexamine the organi-
zational and funding structure of the networks. Taking
into account these and other factors, the Division began
working with investigators, collaborators, advisory com-
mittees, community groups, and a wide range of stake-
holders to help develop the scientific priorities going
forward, and gather input on how best to restructure the
clinical trials programs in anticipation of a grant competi-
tion in 2005. Six scientific priority areas for HIV/AIDS
clinical trials research emerged from this effort:
• HIV Vaccine Research & Development
• Translational Research for Therapeutic Development
• Optimization of Clinical Management
• Microbicide Research & Development
• Mother-to-Child Transmission of HIV
• Prevention Research
Further, the following key guiding principles were identi-
fied:
Responsiveness
Maintain a flexible and responsive approach to emerging
research challenges that ensures that the highest research
priorities are addressed
Efficiency
Improve efficiency through the shared use of key support
services (e.g. laboratories, pharmacies), common data ele-
ments and harmonized data systems, coordinated speci-
men management, shared/standardized training for
common needs, coordinated clinical product acquisition,
distribution and provision.
Coordination
Harmonize and/or integrate HIV/AIDS prevention, vac-
cine and therapeutic research at the scientific and commu-
nity levels, in order to maximize research opportunities
and better respond to public health needs
Capacity Building
Build and strengthen HIV/AIDS research capacity, espe-
cially in resource-limited settings, both domestically and
internationally
Evolution of the NIAID HIV/AIDS clinical trials networksFigure 1
Evolution of the NIAID HIV/AIDS clinical trials networks.
Timeline of NIAID’s HIV/AIDS clinical trials networks by U.S. Government fiscal years (October 1 –
September30).Horizontalbarsdepictnetworks(orpreͲnetworkprograms).Connectionsbetweenbars
representtimepointswhereaprogram/networkwascompetitivelyrenewed.
AACTG AdultAIDSClinicalTrialsGroup
ACTG AIDSClinicalTrialsGroup
ATEU AIDSTreatmentEvaluationUnits
AVEG AIDSVaccineEvaluationGroup
CPCRA
TerryBeirnCommunityProgramsfor
ClinicalResearchonAIDS
CSG CooperativeStudyGroups
ESPRIT
EvaluationofSubcutaneousProleukin
inaRandomizedInternationalTrial
HIVNET HIVNetworkforPreventionTrials
HPTN HIVPreventionTrialsNetwork
HVTN HIVVaccineTrialsNetwork
IMPAACT
InternationalMaternalPediatric
AdolescentAIDSClinicalTrialsGroup
INSIGHT
InternationalNetworkforStrategic
InitiativesinGlobalHIVTrials
MTN MicrobicideTrialsNetwork
PACTG PediatricAIDSClinicalTrialsGroup
PAVE
PreparationforAIDSVaccine
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Strengthen evaluation of network science and manage-
ment to help ensure that the networks address the highest
priority research questions, and function as efficiently and
effectively as possible through the identification and
implementation of best practices, and linking funding to
performance.
To put these scientific and operational priorities into
place, DAIDS developed and issued two "Request for
Application" (RFAs) that differed substantially from pre-
vious network solicitations in several ways.
1. Whereas in the past DAIDS issued multiple "dedi-
cated" RFAs (one for each clinical trials network it
sought to renew), this time a single Leadership Group
RFA was used. Competition through a single RFA
highlighted the importance of the linkages between
the scientific priorities, the applicability of the guiding
principles to all applicant networks, and the decision
not to set a pre-determined funding level for any one
(or group) of the six scientific area(s).
2. Similarly, a single RFA was used to solicit applica-
tions for Clinical Trials Units (CTU) seeking funds to
carry out the future network trials. In previous funding
cycles, DAIDS had issued RFAs for CTU that were 'spe-
cific' to a particular network. The rationale behind the
single CTU RFA was to maximize scientific opportu-
nity and efficiency by allowing investigators (includ-
ing those in resource poor settings) interested in
participating in more than one type of clinical trial
(e.g. vaccines and treatments) to describe their capa-
bilities, and how they would coordinate and harmo-
nize this research, within a single application. This
approach also supports DAIDS goal to help build HIV/
AIDS clinical research capacity by making grant
awards directly to institutions in areas where the dis-
ease has hit the hardest, and where resources are often
constrained.
3. To stimulate the implementation of a cross-cutting
and interdisciplinary research agenda, both RFAs
described four key organizational elements/activities:
1) a new committee comprised of the Principal Investi-
gators of the networks; 2) a new central office of HIV/
AIDS network coordination; and 3) a new Community
Partners group, to enhance community input on all lev-
els, and assure effective representation of (and timely
communication among) the many communities,
(domestic and international) within which the net-
works conduct research, and; 4) coordination, commu-
nication and collaboration across the Institutes and
Centers at NIH that co-sponsor or, in other ways, con-
tribute the HIV/AIDS clinical research networks.
4. To help address the likely scenario of emergent high
priority research opportunities that could require
timely reordering of scientific priorities, new flexible
resource allocations were developed. Both RFAs
described the importance of performance evaluation,
designation of new 'reserve' funds, and a role for exter-
nal advisory bodies to assist in meeting such chal-
lenges.
In June 2006, NIAID announced funding for the restruc-
tured HIV/AIDS clinical trials networks:
• AIDS Clinical Trials Group http://aactg.s-3.com/
• HIV Prevention Trials Network http://www.hptn.org
• HIV Vaccine Trials Network http://www.hvtn.org
• International Maternal Pediatric Adolescent AIDS
Clinical Trials http://impaact.s-3.com/
• International Network for Strategic Initiatives in
Global HIV Trials http://insight.ccbr.umn.edu/
• Microbicide Trials Network http://www.mtnstop
shiv.org
Together, including the network leadership groups and 73
CTU located around the world, funding for the networks
was approximately $285 million in the first year of
awards.
Evaluation goals for the restructured networks
DAIDS considers a comprehensive, integrated evaluation
system a vital element of the new coordinated network
structure. Prior to restructuring (and currently), evalua-
tion activities have been almost exclusively 'network cen-
tric'. Each group's investigator leadership has primary
responsibility for developing and implementing criteria
and processes for assessing the structural components
within a single Network, such as the clinical trials units,
laboratories, data management centers, scientific and
resource committees, and protocol teams. In some
instances, ad hoc expert review panels have provided
external input and evaluative information. While such
single network-focused evaluation activities remain very
important, DAIDS also recognizes the need for a cross-cut-
ting evaluation framework that can support the common
guiding principles that span the restructured network
enterprise (e.g. responsiveness, efficiency, coordination,
capacity building). Such a system can assist DAIDS, its
investigators and collaborators in ensuring that the high-
est priority scientific objectives are addressed; while sup-
porting collaboration, efficiency and research integration
at the cross-network level. While the approach beingPage 4 of 16
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existing within-network evaluation approaches, it will
also define criteria and measures that should be applica-
ble across the networks. It will address a variety of factors
required for the success of clinical research networks,
including activities and processes based within (as well as
across) the investigator networks, constituency communi-
ties, collaborators (e.g. support contractors), and DAIDS
itself (e.g. regulatory, safety, clinical research policy).
The DAIDS HIV/AIDS clinical trials networks are an exam-
ple of a large scale scientific initiative and as such, share
much in common with similar ventures, including broad
goals, a multidisciplinary focus, and emphasis on team
science. However, the HIV/AIDS clinical trials networks
are unique due to aspects related specifically to the con-
duct of international human clinical research, namely: 1)
the reliance on inter-institutional collaboration among
multiple clinical research centers and other collaborators
(e.g., pharmaceutical sponsors, other co-funding agen-
cies); 2) interaction with research constituents/advocates,
including vulnerable populations, and related ethical
issues; 3) compliance with regulatory authorities of mul-
tiple countries which frequently are not harmonized; 4)
the need to maintain a consistent and yet humanitarian
distinction between research and care; 5) achieving bal-
ance between competing clinical research priorities (e.g.
prevention & treatment, domestic & international). Ulti-
mately, DAIDS seeks to support the goals of the clinical
research networks, individually and collectively, toward
research progress against HIV/AIDS.
While most program evaluations are ad hoc, this effort is
unique in that it focuses on creating a system of evalua-
tion. The development of an evaluation system for the
DAIDS clinical research networks encompasses several
integrated phases. Figure 2 displays the focus and
sequencing of these phases leading to an evaluation sys-
tem, including preparation, inquiry, framework develop-
ment, and the evaluation plan. In this paper we describe
the initial phases in this process: the creation of a concep-
tual framework and show how it informs and connects to
the other planning steps.
Engaging stakeholders in constructing an 
evaluation framework
There are numerous challenges in developing appropriate
evaluation systems for large research initiatives. These
include: ensuring the highest-quality evidence; minimiz-
ing burden and the intrusiveness of the system; and yield-
ing data that can satisfy a myriad of scientific, managerial,
financial, and regulatory requirements. One of the most
challenging aspects is identifying the goals of a complex
research initiative across a wide array of stakeholders, each
with a set of expectations as to what constitutes success.
There are few precedents to guide evaluation planning for
such efforts. With the expectation that today's scientific
research enterprise is collaborative and coordinated at
multiple levels, several sources of input are needed to
define the goals of these complex and diverse systems,
develop strategies to work across disciplines in new and
innovative ways, and evaluate the outcomes of collabora-
tive work. Due to the broad range of activities, potential
outputs, and outcomes of large research initiatives, it is
essential that a comprehensive conceptual model to serve
as guide for evaluation is developed [17]. Despite some
initial work describing the evaluation of science and tech-
nology initiatives [6,15,17-21] there is little guidance on
methodologies that would be appropriate, and even less
experience in implementing them [22]. Moreover, while
Process for developing an evaluation systemFigure 2
Process for developing an evaluation system.
Iterative Communication with Stakeholders
Introductions Structured Input Review/Input
Informed
Evaluation
System Plan
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Stage
Inquiry 
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research [23-25], there is little research on the evaluation
of clinical trials research.
Many of the challenges found in evaluating scientific
research initiatives can be mitigated by engaging the stake-
holders of the system, particularly those not often
involved in determining organizational evaluation ele-
ments, in the process of evaluation planning. In this sec-
tion, we describe the approach to engaging stakeholders
in the construction of the conceptual framework to guide
the development of an evaluation system for the DAIDS
clinical research program.
To construct the evaluation framework in an informed
way, the engagement of a diverse array of stakeholders was
deemed necessary. The project sought input from those
who will ultimately be involved in implementing the eval-
uation, including DAIDS staff, Network investigator lead-
ership, the HIV/AIDS Office of Network Coordination,
network evaluation coordinators, community advisory
board representatives, and other government agency staff
with a role in the networks. Our goal was to achieve a
broad sampling of ideas rather than a representative sam-
pling of persons. Thus, the approach was purposive, sam-
pling for heterogeneity. The focus on broad
heterogeneous participation was intended to ensure con-
sideration of a wide variety of view points from those inti-
mately familiar with the networks, provide the necessary
breadth and depth needed to accurately describe the proc-
esses and outcomes of the clinical research networks, and
encourage greater buy-in of the results.
The group of stakeholders to inform this initiative was
expected to include individuals who:
• Are familiar with and understand clinical trials net-
works from a practice perspective
• Have familiarity with government research grant-
making agencies and mechanisms
• Have current knowledge of HIV AIDS related clinical
research
• Understand community perspectives related to HIV
AIDS
• Have operational and management responsibility
for the Division of AIDS
• Have operational and management responsibility
for network(s)
An invitation approach was taken to encourage engage-
ment at al relevant levels within the networks, DAIDS,
NIAID and related offices. Within the networks and
DAIDS, individuals representing a wide range of posi-
tions, job responsibilities and seniority were invited.
The rationale for the involvement of network stakeholders
in the conceptual framework is rooted in participatory
approaches to evaluation where those with a stake in the
program or initiative (partners, funders, beneficiaries)
assume an active and substantive role across all phases of
the evaluation [26,27]. It is believed that participation in
identifying relevant evaluation issues and questions, plan-
ning the evaluation design, selecting appropriate meas-
ures and data collection methods, and gathering and
analyzing data, contribute to enhanced utilization of the
resultant evaluation [26,28]. At its core, this participatory
evaluation activity provided the opportunity for those
with close knowledge of and experience with the DAIDS
clinical research enterprise to proactively design how they
think the enterprise should be evaluated. This approach
has the dual benefit of yielding evaluative information
that is useful and meaningful to the people involved in
the work, and reduce (or minimize the impact of) the
potential imposition of evaluation approaches that are
not appropriate to this endeavor or context imposed from
outside the initiative. A recent review of a dozen large fed-
eral evaluations revealed that the thoroughness of the
design process is the most critical factor in successful
implementation of a large scale evaluation [29].
Within this context, the key method was a structured
group conceptualization process (colloquially referred to
as concept mapping) for gathering and organizing input
from a wide range of sources. Concept mapping is a well
established mixed methods social research approach that
integrates rigorous multivariate statistical analyses with
familiar qualitative processes such as brainstorming, sort-
ing and rating of ideas to create a shared conceptual
model [30,31]. The concept mapping methodology had
been used successfully in similar initiatives [17,18,21,32].
While a concept map is not necessary for the development
of an evaluation system, the concept mapping methodol-
ogy offered several advantages for this development proc-
ess as it presents a rigorous structured approach that can
be used effectively by scientists, managers, and commu-
nity advocates in the process of articulating the conceptual
and logical models that underlie the complex, collabora-
tive work within the scientific research enterprise.
The methodology involves several distinct steps. In the
first part, the idea generation step, stakeholders were
invited to contribute ideas that completed the "focus
statement" sentence: "Coordinated clinical research net-
works will be successful if...". Participants represented
DAIDS staff and leadership, representatives of other gov-
ernment agencies, networks, clinical trials units and clini-
cal research sites, the community and other constituenciesPage 6 of 16
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addition, numerous individual interviews were conducted
and analyzed, together with documents related to the net-
works. The statements submitted in the initial idea gener-
ation were then synthesized into a representative set of
success factors (eliminating duplicates, ensuring clarity
and relevance to the focus statement, achieving a com-
mon level of specificity) that participants could work with
during the idea structuring phase.
The ideas were then structured [33-35] by having stake-
holders sort them into categories of conceptual similarity,
and by rating them on their importance to the success of
the networks, using a 1 (relatively unimportant) to 5
(extremely important) scale.
Using a series of statistical analyses (multidimensional
scaling, then hierarchical cluster analysis), participants'
views about how to categorize the success factors were
aggregated [33-35]. The result is a single, co-authored con-
ceptual map of the territory that illustrates the relation-
ships between ideas [36-38]. The map clusters organize
the input into groups of ideas (major concepts) [39,40].
Participants' ratings of the ideas make it possible to deter-
mine priorities, compare the importance of different suc-
cess factors, assess consensus across groups, and create
value maps for specific groups of stakeholders.
Evaluation framework findings
Overview of the framework
Over 300 stakeholders, representing every sector of the
HIV/AIDS clinical research stakeholder community, con-
tributed ideas that completed the "focus statement" sen-
tence, "Coordinated clinical research networks will be
successful if...". More than 1500 ideas were generated in
response to that focus statement, which were then synthe-
sized into a representative set of 91 ideas that describe
what stakeholders believe are the factors critical to the suc-
cess of the coordinated clinical research networks. Ninety
stakeholders sorted the ideas by similarity/relatedness,
and 308 stakeholders rated the ideas with respect to their
importance to the success of the research networks. Table
1 summarizes the demographic characteristics of those
who completed the ratings.
The concept map representing the success factors is shown
in Figure 3. On the map, each idea (represented by a point
labeled with an identifying number), is shown in relation
to all of the other ideas in the framework. Ideas that are
closer together were deemed similar (or related) by the
individuals who sorted them. In contrast, ideas that are
farther apart on the map were judged to be less conceptu-
ally similar. The clusters, indicated by the shaded poly-
gons, reveal categories of ideas. Larger clusters signify
groups of ideas that are more 'loosely' related, whereas
clusters that appear small (or 'tight') indicate groups of
ideas that were seen as very closely related.
To facilitate communication about the map and its com-
ponents, each cluster has been labeled to describe the the-
matic content of the ideas that comprise the cluster. Just as
with the individual ideas (numbered points), clusters that
are physically closer together were deemed more similar,
according to participants, than those more distant from
one another. It does not matter whether an idea appears
at the top or bottom of the map; a map could be rotated
in any direction, so long as the relationships between the
points are preserved. Distance between points – concep-
tual similarity – is what matters on a concept map. For
more information about concept mapping in the context
of this project, please see Concept Systems, Inc., 2008
[41].
The evaluation framework depicts the broad range of fac-
tors that, in the view of the stakeholders, affect the success
of the coordinated clinical research networks. The results
illustrate the breadth of the activities and outcomes asso-
ciated with this type of large scale, collaborative scientific
research initiative.
Analysis and interpretation of the framework
Focusing on each of the clusters within the concept map,
and the ideas which comprise them (Additional File 1)
allows for a more detailed analysis of the stakeholder-iden-
tified success factors in relation to one another and to the
goals and guiding principles for the restructured clinical
research networks. Additional File 1 shows the individual
ideas that make up each cluster. It also presents the average
importance rating (on a 1–5 scale) for each of the ideas and
the average importance rating of the statements within each
cluster. This table allows us to compare the values that
stakeholders, as a group, place on broad themes (clusters),
as well as individual ideas. Using the ratings to compare
subgroups of participants to each other to determine simi-
larity or divergence of opinion on the importance of the
items on the map to evaluation, we compared ratings of
those who identified themselves as related to different sci-
entific research emphases, (e.g. vaccine research and devel-
opment, translational research/drug development,
optimization of clinical management, and prevention of
HIV infection). Overall, we found a great deal of corre-
spondence between different stakeholder groups' average
cluster ratings, such that a strong correlation existed from
group to group on the conceptual areas that emerged as
being of highest importance and those considered less
important, indicating similarity in the stakeholder-derived
patterns across the elements of the evaluation framework.
Beginning with the cluster labeled Biomedical Objectives
(situated at approximately "1 o'clock" on the map), thisPage 7 of 16
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Table 1: Demographic characteristics of raters
Participant Characteristics Questions Response Choices Frequency %
Years Involved 0–5 years 52 17%
6–10 years 60 19%
11–15 years 73 24%
16–20 years 81 26%
Longer than 20 years 38 12%
did not respond 4 1%
308 100.00%
Primary Area of Science Vaccine Research & Development 53 17%
Translational Research/Drug Development 38 12%
Optimization of Clinical Management, including Co- Morbidities 112 36%
Microbicides 17 6%
Prevention of Mother- to- Child Transmission of HIV 23 7%
Prevention of HIV Infection 23 7%
Other/Not applicable 38 12%
did not respond 4 1%
308 100.00%
Primary Role Network Core 81 26%
Clinical Trials Unit/Site 107 35%
Laboratory 14 5%
Government 47 15%
Community 12 4%
Pharma/Biotech 2 1%
Pharmacy 2 1%
Institutional Review Board/Ethics Committee 0 0%
Non- Governmental Organization 10 3%
Advisory Group/Committee 6 2%
Other 23 7%
did not respond 4 1%
308 100.00%
Health Research Policy and Systems 2009, 7:12 http://www.health-policy-systems.com/content/7/1/12group of ideas focuses on the ultimate aim of the trials
networks to identify prevention and treatment strategies
for HIV/AIDS that can lead to fewer new infections, and
reduced morbidity and mortality in people living with
HIV. Of the eight clusters on the map, Biomedical Objec-
tives emerged as the most important success factor. That
cluster had the highest average importance score (4.11)
(Additional File 1) and it includes the highest rated
(across all the 91 success factors in the framework) indi-
vidual statement, "produce high-quality, scientifically
valid results" (#82 with a rating of 4.74). Traditional peer
review usually places the significance of biomedical
research objectives highest, in terms of importance, when
evaluating research proposals in the biomedical sciences.
That the biomedical objectives of the clinical research net-
works were seen, across stakeholder groups, as the most
important component of success suggests that, at least in
this context, large research initiatives do not differ from
conventional investigator-initiated research.
Moving "clockwise" on the map, the adjacent cluster, Sci-
entific Agenda Setting, is comprised largely of statements
that reflect the need for, and the means by which, net-
works identify their research priorities (Additional File 1).
One of the greatest challenges to a cooperative group is to
make choices from among an array of competing ideas. In
striving to achieve balance in their research agendas, net-
works are constantly weighing factors such as portfolio
diversity, stakeholder input, scientific opportunity, capa-
bility and feasibility. Interestingly, both this Scientific
Agenda Setting cluster, and the Biomedical Objectives cluster
connect very strongly to one of the most important guid-
ing principles for the restructured networks, namely,
responsiveness (Section III A.). That these two clusters
were both rated among the top 3 success factors (average
importance of 4.06), and were seen as highly related (as
indicated by proximity on the map) would appear to
affirm a close alignment between DAIDS goals in restruc-
turing the networks, and what the network stakeholders
believe most important for success.
Next (again moving clockwise) is a large cluster labeled
Collaboration, Communication and Harmonization. The
emphasis of the ideas in this cluster is, as its name implies,
on collaboration and communication both within and
between networks. Statements in this cluster (Additional
File 1) reference collaboration activities at the scientific
level, e.g. "the vision and goals are shared" (#55), as well
Concept map of success factorsFigure 3
Concept map of success factors.
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like training, laboratory, and data management across
networks. The contents of this cluster reflect the restructur-
ing principles of efficiency and coordination, which
emphasize an integrated approach to HIV/AIDS vaccine,
prevention and therapeutics clinical trials, in order to
maximize research opportunities and respond to public
health needs in an increasingly efficient manner. The
importance of linkages across the scientific priority areas
was a key element in the planning process for the restruc-
turing and was the primary impetus for issuing a single
network leadership RFA (as opposed to separate RFAs for
each clinical research area, as had been done in the past).
This was also the major impetus for the establishment of
the Office of HIV/AIDS network coordination, formation
of a network Principal Investigators committee, the
assembly of external scientific advisory bodies to assist
with cross-network scientific prioritization, and strength-
ened coordination across NIH Institutes and Centers.
Interestingly, in contrast to the previous clusters, this
group of ideas was viewed as being among the lowest in
importance among the success factors, with an average
rating of 3.81 (keeping in mind that, in this framework,
least important does not mean unimportant). Given that
many of the statements in the cluster are more process-ori-
ented, it is not surprising that participants view the longer
term, ultimate goals of the network (such as in the Biomed-
ical Objectives and Scientific Agenda Setting clusters) as
more important than the activities that lead to these types
of outcomes. Also, the activities of resource sharing and
inter-network coordination are largely a new demand on
the networks, mandated through the restructuring proc-
ess. While stakeholders recognize this concept as a factor
in the success of the networks, these results would suggest
that it is not yet fully valued by all participants.
Similarly, Operations and Management is also rated rela-
tively lower in importance (3.80) by participants. Again,
this cluster pertains to administrative, rather than scien-
tific aspects of the networks' activities. The statements in
this cluster also indicate that operations and management
depend upon both the networks and DAIDS and suggest
that a comprehensive evaluation of the enterprise
includes both the grantees and the funding agency,
DAIDS.
Attention to funder issues is even more explicit in the
DAIDS Policies and Procedures cluster. As stated by stake-
holders, for the coordinated clinical research networks to
reach their goals, DAIDS policies must "reflect what is
required for good science, protection of human subjects,
and safety", be "transparent", "streamlined" and "clear".
This cluster is very much process oriented, and is rated rel-
atively lower in importance compared to other clusters
(3.96).
The cluster entitled Resource Utilization contains subtopics
that, taken together, describe the concept of resources in
several ways, including human, time, materials and loca-
tions. For example, human resources issues include that
"principal investigators demonstrate scientific leadership
and innovation" and that they are able to "commit ade-
quate time to network activities." Specific attributes of
staff are mentioned, including the need for diversity and
expertise in infrastructure development. Other statements
focus more on issues related to clinical research site capac-
ity and presumably refer to the many HIV/AIDS trials sites
located in developing countries, where access to resources
may be limited. Thus, a common theme across both the
people and the functions is related to making wise use of
resources. This set of statements relates closely to the prin-
ciple of capacity building that figured prominently in the
network restructuring design. The principles of efficiency
and coordination also permeate this cluster. Capacity at
the site level, in particular, is a focus of existing network
evaluation activities. Resource Utilization is the fifth most
important cluster (out of 8), with an average rating of
4.00.
On the left side of the map, Community Involvement
emerged as one of the four highest rated success elements
in the framework at 4.05. Within this cluster, the idea with
the highest importance rating is: "the dignity and human
rights of participants are respected." (#42). In addition to
the protection of human subjects, the statements in this
cluster emphasize the importance of community involve-
ment at all levels and in every stage of study development
and implementation. Adequate training and support
must also be provided to enable this community involve-
ment. This cluster sheds light on a topic that may be of
special significance to clinical trials (by comparison to
other types of research). Community involvement plays
an essential role in ensuring the ethical and scientific
quality of HIV/AIDS clinical research, its relevance to
affected communities, and its acceptance by such commu-
nities (2007 UNAIDS document Ethical considerations in
HIV preventive vaccine research). Community involvement
may also be more challenging with HIV/AIDS (vs. other
diseases) because the communities of interest often reside
in resource poor settings (internationally and domesti-
cally), the social stigmas attached to HIV/AIDS, and the
"disparities in power, wealth, education and literacy
which often exist between the individuals proposing to
conduct research and those who are hardest hit by the HIV
epidemic" [42]. This cluster relates directly to one of the
key components of the network restructuring – the new
Community Partners organization, whose very purpose is
to enhance community input on all levels, and assure
effective representation of and timely communication
among the many communities involved with network
research.Page 10 of 16
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Relevance to Participants. The focus of this cluster is on
ensuring that network research: a) addresses questions of
relevance to the communities and trial participants, and;
b) can produce results leading to preventions and treat-
ments that can be expected to be made available to the
study participants and their communities. Special popula-
tions affected by the HIV/AIDS epidemics raise significant
ethical considerations, some of which are captured in this
cluster. This cluster's location directly adjacent to Biomed-
ical Objectives (signifying that stakeholders found these
elements to be closely related), is also notable, as this clus-
ter addresses issues regarding who is involved in the stud-
ies and who will be the beneficiaries of the results.
Relevance to Participants emerged as a very important suc-
cess factor (4.09), second only to the Biomedical Objectives
of the networks.
The contextual knowledge required to understand or
derive value from the concept map can vary depending on
the user's focus. For those whose interest is to gain a
sophisticated understanding of what the stakeholders of
the HIV/AIDS trials networks believe are the factors criti-
cal to the success of the venture, it would be important to
have: 1) a good familiarity with the NIH's and the investi-
gators' goals for the networks; 2) knowledge of the diver-
sity and multidisciplinarity within the networks; 3) a
background in how clinical trials are conducted; 4) a grasp
on the global pandemic from many aspects including the
epidemiology, demographics, scientific and ethical chal-
lenges; 5) an understanding of the special operational and
logistical challenges of HIV/AIDS clinical research; and 6)
knowledge of the environment/milieu of related/sur-
rounding efforts in which the networks function. With
this kind of contextual knowledge, the relationships
between individual statements (points) and groups of
statements (clusters) on the map would have find their
greatest meaning and could potentially provide the most
insight as to how the data could be utilized.
From evaluation framework to evaluation plan
The concept map of success factors provides a framework
upon which subsequent evaluation planning is continu-
ously built. The concept map was used as the basis for a
logic model of the coordinated clinical research networks
that captures stakeholders' assumptions about how pro-
gram activities lead to desired outcomes [32,43].
Together, the concept map and logic model form an inte-
grated view that captures the complexity of the research
enterprise as well as how it could be evaluated. The con-
cept mapping analysis and results describe the elements of
success and their relative importance, and the logic model
sequences the elements of success temporally and caus-
ally. Graphically, the concept map depicts the multivari-
ate related components of the emerging evaluation
framework, allowing the logic model to represent the
hypothesized causal pathways between elements identi-
fied through the concept mapping process. The current
logic model for the DAIDS clinical research networks is
depicted in Figure 4.
Typically, logic models are constructed from lists of
inputs, activities, outputs, and outcomes, often developed
and considered categorically and independent form one
another. The spatial features found in the concept map are
important because it suggests that those clusters of ideas
that are closer are more likely to be connected in the logic
model. The understanding of how these concepts are
related facilitates a more informed and efficient transition
from the map to the logic model. For example, the loca-
tion of the DAIDS Policies and Procedures cluster in relation
to the Biomedical Objectives cluster suggests they assume
opposite ends of the logic model.
Each box in the logic model corresponds to a component
or cluster obtained from the concept mapping analysis.
The logic model describes a presumed program theory for
the complex research initiative and conveys the sequence
of expected processes and outcomes. In the end, the logic
model developed as a part of this approach was based on
a set of concepts that came directly from the stakeholders;
with the components of the final logic model directly
linked to the original concept mapping ideas submitted
by the stakeholders. Thus, the logic model is more repre-
sentative of the reality of the research networks, than had
only one component of the system developed the model.
This collaboratively developed model serves as a guide for
identifying critical outcome pathways of greatest rele-
vance and for identifying where measurement should be
focused as the plan is implemented.
An Evaluation Measurement Task Force (EMTF), consist-
ing of evaluation coordinators from each of the clinical
trials networks, along with selected DAIDS staff with eval-
uation expertise and knowledge of the networks, assisted
in interpreting the framework and logic model. The EMTF
used the concept map of success factors and the logic
model as the foundation upon which to develop propos-
als for evaluation questions (what should be evaluated)
and measures (how those priority elements should be
evaluated), as well as how these efforts should be opera-
tionalized in the networks and DAIDS. The EMTF's oper-
ationalizing efforts focused on compiling evaluation
tools, processes, and methods from networks, developing
potential indicators for concepts found in the framework,
and identify potential data sources. Thus, the involvement
of the EMTF in further interpretation and planning
ensured a direct correspondence between the map, con-
tent, questions, and measures. This linkage is important as
data is collected and analyzed in the future.Page 11 of 16
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herein, seeks to incorporate a set of measures that, when
taken together, can meet the varied needs of system stake-
holders and yield results from which reasonable inferences
about performance, across the entire clinical trials enter-
prise, can be made, including DAIDS, the trials networks,
community, clinical research support services, etc. In some
areas on the concept map (e.g. Operations and Manage-
ment) evaluation metrics that pertain to well-established
functions and processes, will likely include measures previ-
ously developed, utilized and refined within individual tri-
als networks, and DAIDS. Reuse of existing measures offers
the potential to build on past experience, gain efficiency,
establish baselines and, possibly, performance bench-
marks. In other areas (e.g. cross-network coordination and
collaboration) there may be little experience to draw upon,
in which case new measures may need to be explored and
tested for utility and feasibility.
The outcome of this participatory process will be a draft
evaluation plan that describes the framework and logic
model and associated potential measures, tools and
resources and recommendations for piloting an initial
cross-network evaluation system. With this type of design
in place, evolving iterations of the system can be tested for
feasibility and utility, and modified as needed.
Often, evaluations of research programs are done as one
time, ad hoc events, with little precedent for systems
approaches. (See for exceptions, the National Science
Foundation's Engineering Research Centers [16] and the
National Cancer Institute's Transdisciplinary Tobacco Use
Research Centers (TTURCs) initiative [18,21]). In con-
trast, this effort takes a systems approach to evaluation,
seeking to build rigorous evaluation into the funding
process and lifecycle, so it is seamlessly integrated with
other research activities and provides feedback at key
points to inform decision-making at all levels. Thus, the
final evaluation plan, when developed, will describe sev-
eral key events and milestones that need to be addressed
in a comprehensive evaluation system. This approach also
recognizes that evaluation questions, resources and activ-
DAIDS clinical trials networks logic modelFigure 4
DAIDS clinical trials networks logic model.
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tive, demands upon scientific study, and many other
operational and management factors, and as such, can
inform a flexible evaluation system capable of responding
to the kinds of shifts that take place in a research environ-
ment as dynamic is this one.
Conclusion
The trend toward "big science" calls for the development
of systems for managing and evaluating large scale, multi-
site, collaborative scientific research initiatives. The need
for evaluation systems is particularly great given increas-
ing pressure for accountability for public program out-
comes. Yet, large scale science has its own unique goals,
context and requirements that must be taken into account
when designing ways to evaluate success. An ideal scien-
tific research enterprise has been defined as one that 1)
invests in work that impacts significant social and scien-
tific challenges and responds to new discoveries; 2) fosters
a wide network of relationships that generates relevant
questions, recognizes emerging issues, and sustains signif-
icant, cutting-edge programs of work; 3) develops and
nurtures the human and organizational capacity to con-
duct research; and 4) recognizes and communicates its
impact on the world [44]. To date, there a few examples to
draw upon, which indicate how best to model the success-
ful evaluation of this type of large scale research initiative.
In this context, DAIDS' newly restructured clinical
research networks are an example of a large research initi-
ative seeking to proactively address multiple challenges as
it adapts to meet the ideals of a successful research enter-
prise.
At the highest level, the findings from this process provide
a 'global' view and insight into the network stakeholders'
thoughts, views, and perceptions of the factors critical to
the networks' success. The HIV/AIDS clinical research net-
works comprise thousands of individuals with a variety of
skills and training, working in hundreds of different
organizations, in almost 50 different countries. The diver-
sity of expertise, interests, priorities and cultures repre-
sented in the networks, while vital to their strength, pose
challenges to maintaining a sense of unity of purpose and
teamwork. The findings reveal areas of the network that
stakeholders see as mission critical, and the relative
importance of these different areas. For example, we have
learned, for the first time, that across the board, stakehold-
ers believe that the biomedical objectives selected by the
networks, are the most important factor for network suc-
cess. This finding alone indicates that despite the diversity
inherent in the networks, science is the primary driver.
Given our interest in developing a comprehensive
approach to the evaluation of the networks, this finding
provides a data-driven basis for taking next steps, such as
efforts to understand how the networks determine their
biomedical objectives, how those objectives are vetted,
how they align (or not) with those of other complemen-
tary efforts, how well they match (or not) the strengths
and resources of the networks, and how successful have
the networks been in reaching these objectives. A similar
examination can occur across all clusters of success factors
yielding a great deal of detailed information about what
should be measured and how. Additionally, the findings
allow us to see what other 'clusters' of success factors are
seen by the stakeholders as being related, both conceptu-
ally and in their importance. For example, the findings
reveal that scientific agenda setting (including prioritiza-
tion) and relevance to study participants are both seen as
being closely related to the biomedical objectives and
nearly as important. This provides additional layers of
understanding and again, suggests potential directions in
which the evaluation system development can proceed, in
direct alignment with what the networks themselves see as
the most important activities for achieving success.
The findings from this process allow us to map, in even
greater detail, the success factors at multiple levels (i.e.
statement or cluster) to the demographics of the stake-
holder participants. For instance, we can start to deter-
mine if within one area of science (e.g. HIV vaccines)
certain success factors are seen as more important than
they are viewed by stakeholders working in a different
area, such as HIV therapy. Similarly, we can learn how
stakeholders' time in the networks or their roles relates to
their views of what is important for network success. This
kind of information can help to reveal the basis of conflict
or competition which could be creating obstacles (e.g.
within networks, between networks or network collabora-
tors) and point to activities which could be undertaken to
mitigate such.
Taken together, these findings and the processes described
here are the first of their kind relative to this large research
initiative and provide valuable insights into the nature
and functioning of the HIV/AIDS clinical research net-
works. The concept map and the logic model reflect eval-
uation criteria that account for the goals of multiple
stakeholder groups and inform the first efforts to develop
a systematic approach to evaluating this complex enter-
prise.
In this paper, we described a stakeholder-driven concep-
tual framework development process as an initial step in
the creation of an evaluation system. This participatory
activity engaged scientists, staff, and community advo-
cates with first-hand experience of the initiative, in co-
constructing the framework for an evaluation system. This
stakeholder-driven process served two purposes. It was
designed primarily as a prospective planning tool to iden-
tify the success factors of the coordinated clinical researchPage 13 of 16
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tem. It also enabled a "pulse check" on the extent to which
stakeholders have embraced the goals and guiding princi-
ples embedded in the guiding principles behind the recent
restructuring of the clinical trials networks.
Moreover, we detail how the results of the concept map
relate to the goals of the networks, and point to how the
map can potentially be used to guide the development of
evaluation plans for this complex initiative. That said, the
map can inform other 'views' or interests, for which an
extensive background in HIV/AIDS clinical research
would not be required. For example, for someone inter-
ested in researching the dynamics and complexities of
team science, a contextual knowledge of that field could
inform the interpretation of the HIV/AIDS network con-
cept map (presented herein) in a very different way, and
for a different purpose. In a sense, it depends on the 'lens'
through which the user wishes to view the map, as this
conceptualization activity could support multiple inquir-
ies.
In the context of evaluation of large scale scientific
research initiatives we found support for the idea that "big
science" is accountable for a wider variety of processes,
activities and outcomes than traditionally organized sci-
ence research. This finding is consistent with other writing
on this subject [3,5,19,20,45]. It is not sufficient to simply
apply the same processes of evaluation traditionally asso-
ciated with individual investigator awards because the
expectations of large scale science are broader.
We also found that the sheer size and complexity of the
initiative requires attention to a host of management chal-
lenges that would not be applicable to traditional individ-
ual investigator awards. The recent restructuring of the
coordinated clinical research networks was undertaken to
address many of these management issues, focusing on
efficiency, coordination, responsiveness, capacity build-
ing and evaluation. This assessment indicated an aware-
ness of these management issues among stakeholders, but
revealed that overall, these stakeholders place more value
on outcomes than the administrative and management
processes required to achieve those outcomes.
Finally, we found a number of ideas and concepts that
emerged from the concept map that were consistent with
other evaluation planning efforts carried out in large sci-
entific research initiatives. Concepts related to scientific
outputs and goals, communication and collaboration,
and management policies and procedures have appeared
in other framework development efforts [17,21,32]. Sim-
ilarities notwithstanding, the conceptualization process
was unique to the DAIDS clinical research networks.
Nonetheless, we believe that this work contributes to an
emerging database of "big science" evaluation planning
efforts where concept mapping was used to conceptualize
elements for evaluation. As this collection of conceptuali-
zation projects increases, the potential for meta-analysis
across participants, ideas, data (sorting and rating), and
findings (maps and patterns) is possible.
Several limitations and caveats of this work are worth not-
ing. First, the results of the development of a conceptual
framework are context specific. Although several clusters
that emerged from the concept mapping process were
similar to the content found in other large scale research
evaluation planning processes where concept mapping
has been used, the ideas generated, organized and priori-
tized by the stakeholders were specific to the DAIDS clin-
ical networks. Thus, while limiting the generalizability of
the results, the use of concept mapping had the advantage
of focusing the scope of the evaluation, increasing the
potential for an efficient and sustained evaluation effort.
Second, the results of the development of the conceptual
framework for the evaluation are highly dependent upon
informed and meaningful participation. While we sought
to engage broad-based participation from those that have
a stake in the processes and outcomes of the network
activities, it is clear that some groups had greater numbers
of participants than others. This is fairly typical in partici-
patory evaluation planning. Concept mapping has several
advantages for the management of participation, includ-
ing multiple opportunities for engagement, multiple
forms of input, and multiple products for interpretation.
Given the complexity, size, and scope of the activities of
the clinical research networks, the time spent considering
and engaging stakeholders in the conceptualization proc-
ess is likely to yield benefits in later stages of the evalua-
tion. Additionally, we used mean cluster ratings to
represent the perspectives of the participants. This
approach means that inferences about ratings must be
made with caution. The primary intent of this project was
to sample for heterogeneity to assure that a varied range of
people had an opportunity to volunteer to participate and
that no one who might want to take part would be
excluded. While average ratings may represent well the
views of the participants themselves and of the best repre-
sented subgroups of participants, it is not possible to say
how well such averages represent groups that did not vol-
unteer at comparable rates. In general, sampling issues in
this context are a challenge and the opportunistic volun-
teer sampling used here was intended as a compromise
between inclusion and representativeness. If subgroup
comparisons are desired, we will incorporate a represent-
ative sampling approach.
Through this example, we've described an approach to a
participatory conceptual framework development processPage 14 of 16
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endeavor. These approaches to planning and identifying
key elements of an evaluation system may serve as useful
guidance to others who are also pioneering in this emerg-
ing field.
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